Navigation Links
Novo Nordisk Inc. Appoints Eddie Li as Vice President, Regulatory Affairs
Date:9/7/2011

PRINCETON, N.J., Sept. 7, 2011 /PRNewswire/ -- Novo Nordisk Inc. announced today that Dr. Eddie Li, has been appointed to join the diabetes leader as Vice President, Regulatory Affairs starting September 12.

Reporting to Anne Philips, M.D., Corporate Vice President, Clinical Development, Medical and Regulatory Affairs for North America, Dr. Li brings over 20 years of industry, public sector, and academic experience in the field of regulatory affairs and safety.  He'll be leading Novo Nordisk's U.S. regulatory team, and maintain relationships with key individuals and agencies outside of Novo Nordisk that play a specific role in the U.S. Food and Drug Administration's (FDA) review and approval process.

"Eddie has worked within the FDA and other pharmaceutical peers so he brings a wealth of experience to Novo Nordisk.  He comes to us at a critical time in our company as our portfolio continues to grow," said Anne Phillips, M.D., corporate vice president, Clinical, Medical and Regulatory Affairs.  "The regulatory environment is becoming increasingly complex, and Eddie's background suits our needs to have a senior leader as our main point of contact with the FDA."

Originally trained in medicine and toxicology, Dr. Li has an extensive background in the pharmaceutical industry, joining Novo Nordisk from Sanofi, where he most recently was global head of regulatory affairs for one of its largest therapy areas.  He has also worked at Johnson & Johnson and AstraZeneca.  He also served as a staff reviewer at the FDA.

Eddie studied in the Shanghai First Medical College.  He subsequently completed his Ph.D. in Toxicology at the University of Arkansas for Medical Sciences, and also studied in an M.B.A. program at the University of Delaware.

About Novo Nordisk

Headquartered in Denmark, Novo Nordisk is a global healthcare company with 88 years of innovation and leadership in diabetes care.  The company also has leading positions within hemophilia care, growth hormone therapy and hormone replacement therapy.  For more information, visit www.novonordisk-us.com.


'/>"/>
SOURCE Novo Nordisk Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Novo Nordisk Partners with Minneapolis Community Groups to Support Diabetes Education Programs
2. Novo Nordisk and Partnership of Ivy Equities, LCOR and Intercontinental RE Corp. Announce Lease Agreement for N.J. Pharmaceutical Companys New U.S. Headquarters
3. Novo Nordisk A/S: PharmaVitae Profile
4. Video from Novo Nordisk A/S available on thenewsmarket.com: Novo Nordisk Receives Approval for Victoza in China
5. Novo Nordisk Submits First Recombinant Treatment for Factor XIII Deficiency for U.S. Regulatory Approval
6. Novo Nordisk Creates First Mobile Application to Help Doctors Diagnose Bleeding Disorders
7. Novo Nordisk Intends to Appeal Adverse Ruling in Prandin® (repaglinide) Patent Case
8. Reportlinker Adds Novo Nordisk A/S: PharmaVitae Profile
9. Novo Nordisk A/S and Emisphere Technologies, Inc. Announce License Agreement to Develop Oral Formulation of Insulin for Diabetes
10. Novo Nordisk and Chip Ganassi Racing Team Up for 2011 IZOD IndyCar Series
11. Novo Nordisk and Entertainment Industries Council Work Together to Improve Public Education and Awareness about Diabetes Epidemic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2017)... Tenn. , July 31, 2017 Three Tru-D SmartUVC ... Yongsan, South Korea . Tru-D, short for "Total Room ... and operating rooms after an environmental services (ES) professional cleans the area ... ... "Although the ...
(Date:7/28/2017)... 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), ... ended June 30, 2017, and updated its financial outlook ... For the fiscal third quarter, Hill-Rom reported earnings ... diluted share in the prior-year period. These results reflect ... diluted share primarily related to the non-cash write-down of ...
(Date:7/27/2017)... WARSAW, Ind., July 27, 2017  Zimmer Biomet Holdings, ... the quarter ended June 30, 2017.  The Company reported ... of 1.1% over the prior year period, and an ... approximately 240 basis points of contribution from the LDR ... from the second quarter of 2016, or 0.3% on ...
Breaking Medicine Technology:
(Date:8/16/2017)... ... August 16, 2017 , ... ... affiliations and de novo development, today announced Cumberland Skin Surgery and Dermatology ... Surgery and Dermatology, with offices in both Hermitage and Lebanon, Tennessee, provides comprehensive ...
(Date:8/16/2017)... ... 2017 , ... Paul Vitenas, MD, FACS , is honored to announce ... list identifies the nation’s top physicians, in a variety of specialties. This marks the ... of Castle Connolly’s coveted ranking. , Castle Connolly is the nation’s trusted provider of ...
(Date:8/16/2017)... ... August 16, 2017 , ... SGNA Standards of ... every reprocessing cycle, both between patient procedures and before storage, is a requisite ... as important to the prevention of disease transmission and nosocomial infection as cleaning ...
(Date:8/16/2017)... , ... August 16, 2017 , ... ... $5.99, eBook, 9781498499620    ) shares that during the time of a cancer diagnosis, surgery ... of God's love, and all the many ways God shows love to those ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... an opportunity for men and women to train as hospice volunteers. Volunteers provide ... life-limiting illness. For over 30 years, the agency has trained volunteers to be ...
Breaking Medicine News(10 mins):